Skip to main content
. 2019 Apr 15;145(8):2135–2143. doi: 10.1002/ijc.32307

Table 3.

Sarcoma patient characteristics and management across age groups

Age Age at diagnosis (% of the age groups within the series)
0–17 n = 367 (2.9%) 18–30 n = 772 (6.0%) 31–60 n = 4,451 (34.7%) 61–79 n = 5,789 (45.1%) 80–90 n = 1,343 (10.5%) >90 n = 113 (0.6%) p value1
Histology
Complex genomics
UPS 2 (0.5%) 23 (2.9%) 427 (9.6%) 774 (13.4%) 273 (20.3%) 40 (35·4%) <0.001
LMS 7 (1.9%) 44 (5.7%) 1,038 (23.3%) 1,359 (23.5%) 314 (23.4%) 16 (14·2%) <0.001
Myxofibrosarcoma 2 (0.5%) 8 (1.0%) 214 (4.8%) 445 (7.7%) 135 (10.1%) 14 (12·4%) <0.001
Angiosarcoma 8 (2.2%) 35 (4.5%) 194 (4.4%) 324 (5.6%) 105 (7.8%) 12 (10·6%) <0.001
DDLPS 0 (0%) 10 (1.3%) 412 (9.3%) 892 (15.4%) 192 (14.3%) 11 (9·7%) <0.001
Undifferentiated sarcoma 11 (2.9%) 40 (5.2%) 245 (13.2%) 369 (6.4%) 103 (7.7%) 10 (8·8%) 0.002
Pleomorphic RMS 0 (0.0%) 6 (0.8%) 23 (0.7%) 32 (0.5%) 6 (0.4%) 1 (0.9%) 0.64
GIST 2 (0.5%) 20 (2.6%) 496 (11.1%) 859 (14.8%) 113 (8.4%) 6 (5.3%) <0.001
Translocation sarcoma
Ewing 85 (23.2%) 94 (12.2%) 93 (2.1%) 34 (0.5%) 5 (0.4%) 1 (0·9%) <0.001
Myxoid LPS 7 (1.9%) 61 (7.9%) 307 (6.8%) 99 (1.7%) 10 (0.7%) 1 (0·9%) <0.001
Synovial sarcoma 39 (10.6%) 144 (18.6%) 322 (7.2%) 114 (1.9%) 16 (1.2%) 1 (0·9%) <0.001
Other/not specified 203 (55.3%) 287 (37.2%) 1,080 (24.2%) 488 (8.4%) 71 (5.3%) 0 (0%) <0.001
Gender
Female 153 (41.7%) 362 (46.9%) 2,355 (52.9%) 2,759 (47.7%) 654 (48.7%) 62 (54.9%) <0.001
Male 214 (58.3%) 410 (51.3%) 2096 (47.1%) 3,030 (52.3%) 689 (51.3%) 51 (45.1%)
Grade
1 9 (2.5%) 68 (8.8%) 513 (11.5%) 418 (7.2%) 78 (5.8%) 6 (5.3%) <0.001
2 28 (7.6%) 130 (16.8%) 1,081 (24.3%) 1,541 (26.6%) 353 (26.3%) 24 (21.2%)
3 136 (37.1%) 195 (25.3%) 1,219 (27.4%) 1,735 (30.0%) 515 (38.3%) 39 (34.5%)
UNK/NA 194 (52.8%) 379 (49.1%) 1,638 (36.8%) 2095 (36.2%) 397 (29.6) 44 (38.9%)
Depth
Deep 176 (47.9%) 488 (63.2%) 3,523 (79.2%) 4,361 (75.3%) 894 (66.5%) 63 (55.7%) <0.001
Superficial 15 (4.1%) 70 (9.1%) 543 (12.2%) 896 (15.5%) 349 (26.0%) 45 (39.8%)
Unknown 176 (48.0%) 214 (27.7%) 385 (8.6%) 532 (9.2%) 240 (17.8%) 5 (4.4%)
Size in mm (median) 69.1 72.7 70.2 75.5 69.7 8.0 0.002
Metastatic at diagnosis
Yes 96 (26.1%) 155 (20.1%) 658 (14.7%) 831 (14.3%) 146 (10.8%) 6 (5.3%) <0.001
No 233 (63.5%) 557 (72.2%) 3,406 (76.5%) 4,430 (76.5%) 1,038 (77.3%) 89 (78.8%)
Unknown 38 (10.4%) 60 (7.8%) 387 (8.7%) 528 (9.1%) 159 (11.8%) 18 (15.9%)
Biopsy before
Yes 299 (81.5%) 555 (71.9%) 763 (62.1%) 3,690 (63.7%) 906 (87.5%) 72 (63.7%) <0.001
No 35 (9.5%) 162 (21.0%) 1,365 (30.7%) 1,644 (28.4%) 346 (25.8%) 32 (28.3%)
Unknown 33(9.0%) 55 (7.1%) 323 (7.3%) 455 (7.9%) 91 (6.8%) 9 (8.0%)
Imaging < surgery
Yes 311 (84.7%) 639 (82.8%) 3,406 (76.5%) 4,281 (74.0%) 915 (68.1%) 64 (66.6%) <0.001
No 8 (2.2%) 29 (3.8%) 199 (4.5%) 326 (5.8%) 128 (9.5%) 14 (12.4%)
Unknown 48 (13.1%) 104 (13.5%) 846 (19.0%) 1,172 (20.2%) 300 (22.3%) 35 (31.0%)
Neoadjuvant treat
Yes 82 (22.3%) 82 (10.6%) 310 (7.0%) 325 (5.6%) 36 (2.7%) 3 (2.7%) <0.001
No 25 (6.8%) 139 (18.0%) 981 (22.0%) 1,308 (22.6%) 277 (20.6%) 31 (27.4%)
Total 260 (70.8%) 551 (71.4%) 3,160 (71.0%) 4,156 (71.8%) 1,030 (76.7%) 79 (69.9%)
Surgery in NETSARC
Yes 146 (39.8%) 291 (37.7%) 1,529 (34.4%) 1849 (31.9%) 351 (26.1%) 16 (14.2%) <0.001
No/No surgery/UNK 221 (60.2%) 481 (62.3%) 2,922 (65.6%) 3,940 (68.1%) 992 (73.9%) 97 (85.8%)
Excision margins of last surgery
R0 122 (33.2%) 307 (39.8%) 1,799 (40.4%) 2,229 (38.5%) 392 (29.2%) 29 (25.7%) <0.001
R1 47 (12.5%) 105 (13.6%) 721 (16.2%) 997 (17.2%) 254 (18.9%) 18 (15.9%)
R2 9 (2.5%) 42 (5.4%) 197 (4.4%) 235 (4.1%) 58 (4.3%) 7 (6.2%)
Other/Unknown 189 (51.5%) 318 (41.2%) 1,734 (38.9%) 2,328 (40.2%) 639 (47.6%) 59 (52.2%)

Bold indicates significant p value (p < 0.05).

1

Chi2 test.